Core 1 and extended core 1 O-glycans

Core 1 and extended core 1 O-glycans are truncated carbohydrate structures, such as the Thomsen-Friedenreich (T) antigen, that are aberrantly expressed on the surface of many solid and hematological tumor cells [1, 9]. These glycans are also found on specific immunosuppressive cell populations, including regulatory T cells (Tregs), granulocytic myeloid-derived suppressor cells (gMDSCs), and neutrophils [4, 11]. In malignant contexts, the normal elongation of O-glycans is disrupted, leading to the accumulation of these truncated forms which contribute to tumor progression and immune evasion by interacting with inhibitory receptors like Siglecs [6, 17]. Therapeutic agents like the monoclonal antibody NEO-201 specifically bind to these glycans to eliminate both the tumor cells and the immunosuppressive cells in the tumor microenvironment through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [11, 15]. This dual targeting approach is designed to reduce the immunosuppressive burden and enhance the activity of other immunotherapies, such as PD-1 inhibitors [9, 15].

Other names

T antigenThomsen-Friedenreich antigenTruncated O-glycansNEO-201 targetCore 1 O-glycansExtended core 1 O-glycans

Monoclonal antibody-mediated depletion of target-expressing cells via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).